Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab

Por Delmar, Paul, Irl, Cornelia, Tian, Lu
Publicado no Contemp Clin Trials Commun (2017)

A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer’s disease

Por Wang, Guoqiao, Berry, Scott, Xiong, Chengjie, Hassenstab, Jason, Quintana, Melanie, McDade, Eric M., Delmar, Paul, Vestrucci, Matteo, Sethuraman, Gopalan, Bateman, Randall J.
Publicado no Stat Med (2018)

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Por Ostrowitzki, Susanne, Lasser, Robert A., Dorflinger, Ernest, Scheltens, Philip, Barkhof, Frederik, Nikolcheva, Tania, Ashford, Elizabeth, Retout, Sylvie, Hofmann, Carsten, Delmar, Paul, Klein, Gregory, Andjelkovic, Mirjana, Dubois, Bruno, Boada, Mercè, Blennow, Kaj, Santarelli, Luca, Fontoura, Paulo
Publicado no Alzheimers Res Ther (2017)

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

Por Nave, Stephane, Doody, Rachelle S., Boada, Mercè, Grimmer, Timo, Savola, Juha-Matti, Delmar, Paul, Pauly-Evers, Meike, Nikolcheva, Tania, Czech, Christian, Borroni, Edilio, Ricci, Benedicte, Dukart, Juergen, Mannino, Marie, Carey, Tracie, Moran, Emma, Gilaberte, Inma, Muelhardt, Nicoletta Milani, Gerlach, Irene, Santarelli, Luca, Ostrowitzki, Susanne, Fontoura, Paulo
Publicado no J Alzheimers Dis (2017)